4 Antibiotics that shouldn't be used (for certain situations)

Why can an antibiotic show "susceptible" on a culture report and still fail? This video explains how pharmacokinetics (PK), pharmacodynamics (PD), and the site of infection decide whether an antibiotic actually works, using four classic examples: nitrofurantoin, moxifloxacin, tigecycline, and daptomycin. A susceptibility report tells you a drug can kill the bacteria in the lab. It doesn't tell you whether the drug reaches the infection, what concentration it achieves there, or whether the local environment shuts it down. We cover: What MICs and clinical breakpoints (CLSI) actually mean Nitrofurantoin: why it works for cystitis but not pyelonephritis (renal parenchyma penetration) Moxifloxacin vs. ciprofloxacin and levofloxacin: why one fluoroquinolone isn't used for UTIs (lipophilicity, metabolism, urinary excretion) Tigecycline: why a huge volume of distribution makes it a poor choice for bacteremia and bloodstream infections Daptomycin: why it treats MRSA bacteremia but fails in pneumonia (inactivation by pulmonary surfactant) By the end, you'll have a five-question framework for choosing an antibiotic beyond the susceptibility report: Where is the infection? Does the drug reach it? What concentration does it achieve? Does the local environment change its activity? Does it hit the PK/PD target? Great for pharmacy students, medical students, nursing students, PA and NP students, residents, and anyone studying infectious disease, antimicrobial stewardship, or for exams like the NAPLEX, USMLE, and BCIDP. ⏱️ Chapters 0:00 – Why "susceptible" isn't enough 0:00 – MICs and clinical breakpoints explained 0:00 – Pharmacokinetics vs. pharmacodynamics 0:00 – Nitrofurantoin and pyelonephritis 0:00 – Moxifloxacin and UTIs 0:00 – Tigecycline and bloodstream infections 0:00 – Daptomycin and pneumonia 0:00 – 5 questions to ask before choosing an antibiotic References IDSA 2025 Guideline on Complicated Urinary Tract Infections IDSA 2026 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections FDA prescribing information: moxifloxacin, daptomycin, tigecycline This video is for educational purposes only and is not medical advice. Always follow current guidelines, institutional protocols, and clinical judgment. #Pharmacology #InfectiousDisease #Antibiotics